1. Home
  2. ALGN

as 05-21-2024 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Industrial Specialties

Nasdaq

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Founded: 1997 Country:
United States
United States
Employees: N/A City: TEMPE
Market Cap: 21.1B IPO Year: N/A
Target Price: $351.25 AVG Volume (30 days): 596.3K
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 6.06 EPS Growth: 49.63
52 Week Low/High: $176.34 - $413.20 Next Earning Date: 04-24-2024
Revenue: $3,916,544,000 Revenue Growth: 5.72%
Revenue Growth (this year): 6.75% Revenue Growth (next year): 9.60%

Share on Social Networks:

Stock Insider Trading Activity of Align Technology Inc. (ALGN)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
LACOB JOSEPH ALGN Director Feb 27 '24 Sell $313.01 10,000 $3,130,075.00 146,994 SEC Form 4
LACOB JOSEPH ALGN Director Feb 27 '24 Sell $302.97 10,524 $3,188,506.80 136,470 SEC Form 4
LACOB JOSEPH ALGN Director Feb 27 '24 Sell $303.59 3,676 $1,115,996.47 132,794 SEC Form 4
LACOB JOSEPH ALGN Director Feb 27 '24 Sell $304.76 800 $243,805.20 131,994 SEC Form 4
HOGAN JOSEPH M ALGN President and CEO Nov 9 '23 Buy $192.50 5,194 $999,845.00 208,664 SEC Form 4